Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N5/00—Radiation therapy
  • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
  • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Definitions

• the present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant.
• the compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR.
• CRPC castration- resistant prostate cancer
• AR functional androgen receptor
• AR-mediated processes and the availability of intra-prostatic intracellular androgens.
• SEPC early stage prostate cancer
• CRCP is not responsive to classical AR antagonist
• the present disclosure provides a compound of Formula I:
• each of Ri and R 2 is independently hydrogen, alkoxy, or CN; R 3 is hydrogen or halo; and wherein at least one of Ri, R 2 , R 3 is not hydrogen.
• Ri or R 2 can be CN.
• Ri can be alkoxy.
• Ri can be methoxy.
• R 3 can be halo.
• R 3 can be chloro.
• R 5 is heteroaryl, arylalkyl, cycloalkenyl, alkoxyalkyl, optionally substituted with one or more R 12 substituents;
• R 12 is -(CH 2 ) n -C0 2 H, wherein n is 0, 1, 2, or 3; and with the proviso that R 5 is not imidazole.
• R 5 can be heteroaryl.
• R 5 can be pyridyl.
• R 5 can be 3-pyridyl.
• R5 can be triazole.
• R5 can be arylalkyl.
• R5 can be cycloalkenyl.
• R5 can be alkoxyalkyl.
• R 12 can be -C0 2 H or -CH 2 C0 2 H.
• the present disclosure provides a pharmaceutical composition
• a pharmaceutical composition comprising one or more compounds or pharmaceutically acceptable salts of the present disclosure and a pharmaceutically acceptable excipient, carrier or diluent.
• the present disclosure provides a method of treating cancer, a disease or a condition in a subject in need thereof, comprising: administering to the subject an effective amount of a compound, pharmaceutically acceptable salt or composition of the present disclosure.
• the method can further comprise administering to the subject an effective amount of an anti-androgen, a CYP 17 inhibitor, a luteinizing hormone-releasing hormone agonist, a drug for preventing androgen production, an estrogen, or a chemotherapy drug.
• the compound, pharmaceutically acceptable salt or composition is administered in combination with a hormone therapy, a chemotherapy, a radiation therapy, an immunotherapy, or surgery.
• the cancer, the disease or the condition can be selected from prostate cancer, breast cancer, ovarian cancer, urogenital cancer, or prostate hyperplasia.
• the present disclosure provides a method for inhibiting androgen receptor activity in a subject in need thereof, comprising administering to the subject an effective amount of a compound, pharmaceutically acceptable salt or composition of the present disclosure
• the present disclosure provides a method for inhibiting androgen receptor activity in a cell, comprising contacting the cell with an effective amount of a compound, pharmaceutically acceptable salt or composition of the disclosure, and thereby inhibiting androgen receptor activity in the cell.
• the present invention provides a method for synthesizing a compound or pharmaceuticall acceptable salt of Formula I, comprising the steps of:
• X can be halo; each of Ri and R 2 can be independently hydrogen, alkoxy, or CN; R3 can be hydrogen or halo; and wherein at least one of R ls R 2 , R3 can be not hydrogen.
• the compound of Formula la is deformylated with a Pd catalyst.
• the present disclosure provides a method for synthesizing a compound or harmaceutically acceptable salt of Formula II, comprising the steps of:
• Rio can be alkyl or aryl, optionally substituted by one or more Rn substituents; and Rn can be halogen, alkoxy, or CN.
• the compound of Formula Ila can be reduced by NaBH 4 .
• the present disclosure provides a method for synthesizing a compound or pharmaceutically acceptable salt of Formula III, comprising:
• R 5 can be heteroaryl, arylalkyl, cycloalkenyl, alkoxyalkyl, optionally substituted with one or more R 12 substituents; and R 12 can be -(CH 2 ) n -C0 2 H, wherein n is 0, 1, 2, or 3; with the proviso that R 5 is not imidazole.
• the acylating agent R 5 C(0)Y can be an activated ester.
• Y can be -OC(0)R 5 .
• Y can be R 5 .
• Figure 1 illustrates the chemical structures of flutamide (1), bicalutamide (2), abiraterone acetate (Zytiga, 3a), abiraterone alcohol (3b), TAK-700 (Orteronel, 4), VN/124-1 (TOK-001 or Galeterone, 5), MDV3100 (Enzalutamide, 6) and ARN-509 (7).
• FIG. 2 illustrates the chemical structures of dihydrotestosterone (DHT, 8), metribolone (R1881, 9), fulvestrant (10) and GW5638 (11).
• Figure 3 provides a stereo view of the binding mode of 5 (cap, green) in the active site hAR.
• FIG. 4 summarizes the effects of the compounds on dihydrotestosterone (DHT)- stimulated transcription of AR.
• Figure 5A illustrates the competitive inhibition of [3HJR1881 binding of compounds 2, 3b, 5, 6 and 36 to AR in LNCaP cells;
• Figure 5B illustrates the competitive inhibition of
• Figure 6A-E illustrates the differential effect of compounds on suppressing AR expression in LNCaP and CWR22rvl prostate cancer cells.
• Figure 7 summarizes the effects of compounds 5, 32, 36, 47 and 48 on: i) cell viability (blue); ii) DHT -induced AR transactivation (green); and iii) AR protein expression following treatment with 15 ⁇ of each compound for 24 h.
• Figure 8A provides a stereoview of the binding mode of 47 (cap, brick red) in the active site of AR;
• Figure 8B provides a stereoview of the binding mode of 36 (cap, element color) in the active site of AR.
• Figure 9 is a synthetic scheme for the synthesis of C-17 benzimidazole compounds.
• Figure 10 is a synthetic scheme for the synthesis of C-16 substituted compounds.
• Figure 11 a synthetic scheme for the synthesis of C-3 modified compounds.
• C-3 modifications Molecular docking of 5 with human androgen receptor (hAR) ligand binding domain shows that C-3 hydroxyl group forms multiple hydrogen bonding with Arg-752 and Phe764 ( Figure 3).
• Arginine is a polar hydrophilic amino acid which contains a positively charged guanidine group.
• various C-3 modified compounds were designed and synthesized (33-49, Figure 11).
• the present disclosure provides a compound of Formula I:
• each of Ri and R 2 is independently hydrogen, alkoxy, or CN; R 3 is hydrogen or halo; and wherein at least one of R ls R 2 , R 3 is not hydrogen.
• Ri can be CN.
• R 2 can be CN.
• Ri can be alkoxy (e.g. methoxy).
• R 3 can be halo (e.g. chloro).
• Exemplary compounds of Formula I include but are not limited to:
• Rio can be alkyl (e.g. isopentyl). In other examples, Rio can be aryl (e.g. phenyl). In further examples, Rio can be further substituted with one or more alkoxy groups (e.g.
• Exemplary compounds of Formula II include but are not limited to:
• R 5 is heteroaryl, arylalkyl, cycloalkenyl, alkoxyalkyl, optionally substituted with one or more R 12 substituents;
• R 12 is -(CH 2 ) n -C0 2 H, wherein n is 0, 1, 2, or 3; with the proviso that R 5 is not imidazole.
• R 5 can be heteroaryl.
• R 5 can be pyridyl (e.g. 1 -pyridyl, 2-pyridyl, 3 -pyridyl).
• R5 can be triazole.
• R5 can be arylalkyl (e.g. benzyl).
• R 5 can be cycloalkenyl (e.g. cyclohexenyl).
• R 5 can be alkoxyalkyl (e.g. methoxymethyl).
• R 12 can be -C0 2 H or -CH 2 C0 2 H.
• Exemplary compounds of Formula III include but are not limited to:
• the present disclosure provides a method for synthesizing a compound of Formula I by allowing a compound of Formula A to react with a benzimidazole of Formula D under conditions that are effective for synthesizing a compound of Formula la: FsrmiiSa A
• X can be halo; each of Ri and R 2 can be independently hydrogen, alkoxy, or CN; R 3 can be hydrogen or halo; and wherein at least one of R ls R 2 , R 3 is not hydrogen.
• the compound of Formula A can react with the benzimidazole under basic conditions.
• the compound of Formula la can then be deformylated and hydro lyzed to afford the compound of Formula I.
• the deformylation can be in the presence of a catalyst.
• the catalyst can be a Pd catalyst (e.g. 10% Pd on carbon).
• the hydrolysis can be performed in the presence of an aqueous base.
• the present disclosure provides a method for synthesizing a compound of Formula II by allowing a compound of Formula B to react with a substituted amine RioNH 2 under conditions that are effective for s nthesizin a compound of Formula Ila:
• the compound of Formula Ila can then be reduced to afford the compound of Formula II.
• the compound of Formula Ila can then be reduced by a reducing agent (e.g. NaBH 4 ).
• the present disclosure provides a method for synthesizing a compound of Formula III allowing a compound of Formula C to react with an acylating agent RsC(0)Y under conditions that are effective for synthesizing a compound of Formula III:
• R5 can be heteroaryl, arylalkyl, cycloalkenyl, alkoxyalkyl, optionally substituted with one or more R 12 substituents; and R 12 can be -(CH 2 ) n -C0 2 H, wherein n is 0, 1, 2, or 3; with the proviso that R 5 is not imidazole.
• the present disclosure also provides a pharmaceutical composition
• a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more of the compounds or salts discussed above.
• Suitable pharmaceutically acceptable carriers described herein for example, vehicles, adjuvants, excipients, and diluents, are well-known to those skilled in the art and are readily available to the public.
• the choice of carrier will be determined, in part, by the particular composition and by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of the pharmaceutical compositions of the present invention.
• the present disclosure also relates to method of treating diseases or conditions, such as cancer or other urogenital diseases and conditions, including, without limitation, breast cancer, prostate cancer, other urogenital cancers, prostate hyperplasia, or other androgen-related diseases or conditions, by administering to a subject in need thereof an effective amount of a compound or salt in accordance with the present disclosure.
• diseases or conditions such as cancer or other urogenital diseases and conditions, including, without limitation, breast cancer, prostate cancer, other urogenital cancers, prostate hyperplasia, or other androgen-related diseases or conditions
• treating is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving, etc., one or more of the symptoms associated with the prostate disease.
• prostate diseases examples include, e.g., prostatic hyperplasia (BPH), and prostate cancer (e.g., prostatic adenocarcinoma).
• BPH prostatic hyperplasia
• prostate cancer e.g., prostatic adenocarcinoma
• the treatment can be prophylactic or therapeutic.
• prophylactic refers to any degree in inhibition of the onset of a cellular disorder, including complete inhibition, such as in a patient expected to soon exhibit the cellular disorder.
• “Therapeutic” refers to any degree in inhibition or any degree of beneficial effects on the disorder in the mammal (e.g., human), e.g., inhibition of the growth or metastasis of a tumor.
• suitable methods of administering a compound or salt of the present disclosure to an animal, e.g., a mammal such as a human, are known.
• a particular route can provide a more immediate and more effective result than another route.
• Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of one or more compound or salt of this disclosure dissolved in a diluent, such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions.
• a diluent such as water or saline
• capsules, sachets or tablets each containing a predetermined amount of the active ingredient, as solids or granules
• suspensions in an appropriate liquid and (d) suitable emulsions.
• Tablet forms can include one or more of lactose, mannitol, cornstarch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically acceptable and compatible carriers.
• Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
• a flavor usually sucrose and acacia or tragacanth
• pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
• the compound or salt of the disclosure can be made into aerosol formulations to be administered via inhalation.
• aerosol formulations can be placed into pressurized acceptable propellants, such as
• dichlorodifluoromethane such as HFC 134a and/or 227), nitrogen, and the like.
• Formulations suitable for parenteral administration include aqueous and non-aqueous solutions, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
• the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
• Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
• the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to affect a therapeutic response in the animal over a reasonable time frame.
• the specific dose level and frequency of dosage may vary, depending upon a variety of factors, including the activity of the specific active compound, its metabolic stability and length of action, rate of excretion, mode and time of administration, the age, body weight, health condition, gender, diet, etc., of the subject, and the severity of, for example, the prostate cancer or hyperplasia. Any effective amount of the compound can be administered, e.g., from about 1 mg to about 500 mg per day, about 50 mg to about 150 mg per day, etc.
• a suitable dosage for internal administration is 0.01 to 100 mg/kg of body weight per day, such as 0.01 to 35 mg/kg of body weight per day or 0.05 to 5 mg/kg of body weight per day.
• a suitable concentration of the compound in pharmaceutical compositions for topical administration is 0.05 to 15% (by weight), preferably 0.02 to 5%, and more preferably 0.1 to 3%).
• the compound or salt of this disclosure can be administered in such dosages in any form by any effective route, including, e.g., oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, spray, inhalation, subcutaneous, intravenous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, etc.
• any effective route including, e.g., oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, spray, inhalation, subcutaneous, intravenous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, etc.
• the compound or salt of the present disclosure can be administered alone, or in combination with any ingredient(s), active or inactive, such as with a
• the compound or salt of the present disclosure can also be used in combination with other cancer treatments and drugs.
• the compound or salt of this disclosure can be used as a part of or in combination with known cancer treatments such as hormone therapy, chemotherapy, radiation therapy, immunotherapy, and/or surgery.
• known cancer treatments such as hormone therapy, chemotherapy, radiation therapy, immunotherapy, and/or surgery.
• one or more of the compounds or salts described above is/are used in combination with one or more known and available drugs or other compounds.
• Exemplary drugs and/or hormones for use in combination with the compounds or salts of this invention for treating cancer or other conditions or diseases discussed above include, without limitation, anti-androgonens such as flutamide and nilutamide; a CYP17 inhibitor such as abiraterone; luteinizing hormone-releasing hormone agonists such as leuprolide, goserelin and buserelin; drugs that prevent the adrenal glands from making androgens such as ketoconazole and aminoglutethimide; and estrogens.
• Other suitable and exemplary cancer drugs, common for use in chemotherapy include, without limitation, cyclophosphamide, methotrexate,
• 5-Fluorouracil (5-FU), doxorubicin, carboplatin, carmustine, chlorambucil, cisplatin,
• cyclophosphamide dacarbazine, ifosfamide, mechlorethamin, melphalan, procarbazine, bleomycin, doxorubicin, idarubicin mitoxantrone, chlorodeoxyadenosine, cytarabine,
• the compounds or salts of this disclosure can be administered to a patient at any time as determined by the treating physician.
• the compounds or salts of this disclosure can be administered for treating a patient during one or more of Stages II-IV of the cancer.
• FIG. 10 The intermediate imines 23, 26 and 29 were synthesized by refluxing z ' -pentylamine, aniline and 3,4-dimethoxyaniline, respectively with 14 in ethanol in presence of molecular sieves. Subsequent reduction of these imines with sodium borohydride (NaBH 4 ) in ice-cold methanol gave 3-acetoxy-16-alkylamine intermediates 24, 27 and 30, respectively. Following hydrolysis of the 3P-acetoxy groups in compounds 24, 27 and 30, the desired 16-substituted compounds, 25, 28, and 31, respectively, were obtained in excellent yields.
• sodium borohydride NaBH 4
• ⁇ 4 -3- ⁇ compound (32) was synthesized via modified Oppenauer oxidation of 5 by using N- methylpiperidone and aluminum isopropoxide. Oxidation of 5 with Dess-Martin periodinane in dichloromethane (DCM) afforded the ⁇ 5 -3- ⁇ compound 33 in 70% yield.
• DCM dichloromethane
• the mesyl (34) and tosyl (35) derivatives of 5 were readily synthesized by reacting with methanesulfonyl and toluenesulfonyl chloride, respectively.
• the C-3 oxime derivatives (hydroxime: 36, phenyloxime: 37, methyloxime: 38 and benzyloxime: 39) were obtained by refluxing ketone (32) with the respective substituted hydroxylamine hydrochloride, using ethanol/methanol solvent mixture in presence of sodium acetate.
• ketone 32
• ethanol/methanol solvent mixture in presence of sodium acetate.
• biologically active oxime 366
• was further purified to separate E- and Z- geometrical isomers by combined purification methods (column chromatography, preparative TLC, and recrystallization). Addition of MeLi to the C-3-keto group of 32 afforded two distereomeric (3a- and 3 ⁇ ) alcohols (40) which we did not separate due to modest biological activity.
• the ester derivatives (41 - 46) of 5 were synthesized from 5 by two different methods as described below.
• the pyridinecarboxylates (41, 42 and 43) and carboxylate of 1,3-phenyldiacetic acid (44) of 5 were prepared using the mixed anhydride method via condensations with the respective anhydrides ( pyridinecarboxylic acid/1, 3 -phenyl diacetic acid and 2-methyl-6- nitrobenzoic) in the presence of 4-dimethylaminopyridine (DMAP) and triethylamine (TEA) with varying yields (39-90%).
• DMAP 4-dimethylaminopyridine
• TAA triethylamine
• the ester 45 (72% yield) and 46 (28%> yield) were synthesized by refluxing 1,2,3,6-tetrahydropthalic and diglycolic anhydrides respectively with 5 in the presence of DMAP in pyridine.
• the carbamates (imidazole: 47, 2-mehtylimidazole: 48 and 1,2,4- triazole: 49) were synthesized in modest to high yield (67-80%>) by reacting 5 with 1,1- carbonylbis(2-methylimidazole) (CDI) and carbonylditriazole (CDT), respectively in acetonitrile and DMC solvent mixture.
• CDI 1,1- carbonylbis(2-methylimidazole)
• CDT carbonylditriazole
• Example 2 Biological Effects of Compounds on Transcriptional Activation of Androgen Receptor
• luciferase reporter assay was used to determine whether the novel compounds also affect AR transcriptional activation (screening assay).
• luciferase experiment utilizing LNCaP cells dual transfected with the probasin luciferase reporter construct ARR2-luc and the Renilla luciferase reporting vector pRL-null was used.
• the LNCaP cells were purchased from American Type Culture Collection- ATCC (Rockville, MD, USA). Cells were maintained in ATCC recommended culture media with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, USA) and 1% FBS (Atlanta Biologicals, Lawrenceville, GA, USA) and 1% FBS (Atlanta Biologicals, Lawrenceville, GA, USA) and 1%
• CWR22rvl cells are a gift from Dr. Marja Nevalainen of Thomas Jefferson University, Philadelphia.
• LNCaP cells were transferred to steroid- free medium 3 days before the start of the experiment and plated at 1 x 10 5 per well in steroid-free medium.
• the cells were dual transfected with ARR2-Luc and the Renilla luciferase reporter vector pRL-null. After a 24-h incubation period at 37 °C, the cells were incubated in fresh phenol red-free RPMI 1640 containing 5% charcoal-stripped fetal bovine serum and treated with 10 nmol/L dihydrotestosterone, ethanol vehicle, and/or the selected compounds in triplicate.
• the cells were washed twice with ice-cold Dulbecco's PBS and assayed using the Dual Luciferase kit (Promega) according to the manufacturer's protocol.
• Cells were lysed with 100 ⁇ , of luciferase lysing buffer, collected in a microcentrifuge tube, and pelleted by centrifugation. Supernatants (20 ⁇ , aliquots) were transferred to corresponding wells of opaque 96-well multiwall plates. Luciferase Assay Reagent was added to each well, and the light produced during the luciferase reaction was measured in a Victor 1420 scanning multiwell spectrophotometer (Wallac, Inc.).
• Luciferase expression was increased by approximately 100-fold after 10 nM DHT treatment for 24 hours.
• the ability of the novel compounds (10 ⁇ ) to affect DHT mediated AR transcription was assessed.
• Figure 4 shows the effects of our most potent compounds. These compounds were able to substantially inhibit DHT mediated transcription, with inhibition ranging from -65-100%.
• compound 5 reduces androgen action through inhibition of androgen binding and subsequently reduces AR mediated transcriptional activity.
• Whole cell competitive binding assays with the synthetic ligand methyltrienolone (R1881) were used to assess the AR binding affinities of the novel compounds in comparison to 5, and the FDA approved anti-androgens bicalutamide (2) and enzalutamide (6), and abiraterone alcohol (3b) as shown in Figure 5A.
• the androgen receptor competitive binding assays were performed with the synthetic androgen methyltrienolone [ HJR1881.
• Wells in 24-well multiwell dishes were coated with poly- 1-lysine (0.05 mg/ml) for 30 minutes, rinsed with sterilized, distilled water, and dried for 2 hours.
• poly- 1-lysine 0.05 mg/ml
• the data was analyzed, including Ka and B max determination, by nonlinear regression using Graphpad Prism software (GraphPad Software, Inc, San Diego, CA).
• concentration of [ HJR1881 required to almost saturate AR in both cell lines was established (5.0 nM)
• the ability of the test compounds (1 nM-10 ⁇ ) to displace [ 3 H]R1881 (5.0 nM) from the receptors was determined as described above.
• the IC 50 of each compound was determined by nonlinear regression with Graphpad Prism software (GraphPad Software, Inc, San Diego, CA).
• AR-binding assays using LNCaP cells shows that 6 was not as potent as previously reported for assays using LNCaP cells transfected with wild type AR 10 and was not significantly different from the binding affinity of bicalutamide (2).
• the new compounds were not as potent as 5 at inhibiting androgen binding at the concentrations tested ( Figure 5B).
• compound 36 showed the strongest inhibition of [ HJR1881 binding of all the new compounds tested (-40%) at 10 ⁇ .
• 36 inhibited [ 3 H]R1881 binding to by -80%, while 43 inhibited by -53%.
• the most effective AR antagonist, 47 did not strongly compete for the AR binding site, exhibiting only 20% displacement at a 30 ⁇ concentration. It is relevant to state here that other investigators have recently reported the discovery of small-molecule androgen receptor down-regulators and anti-androgens that bind weakly to the AR.
• Example 4 Effects on AR Down-Regulation, Transactivation and Anti-Pro liferative Activity
• LNCaP cells were plated in 8 chamber vessel tissue culture treated glass slide (0.025 X 10 6 cells/well), for 12h and then treated with 5uM of VN/124-1 or VNPT55 for 48h. Cells were washed twice with PBS and fixed in 3.7%
• AR-3 also called AR-V7
• galeterone (5) and some of our new compounds, 31, 32, 36 and 47 caused significant down-regulation of both full-length and truncated AR in CWR22rvl prostate cancer cell line.
• AR-3 was more susceptible to the compounds than the full-length AR in this cell line.
• MDV3100 did not affect the expression levels of either full-length or splice variant forms of AR.
• a number of natural products and related analogs have been shown to degrade both full-length and truncated AR in several human prostate cancer cell lines.
• ASC-J9 that possesses excellent drug-like properties, most of these compounds are poor drug candidates because of modest potencies and/or toxic nature.
• the unique AR depleting agents provided in the present disclosure may be more effective against CRPC than agents that obligatorily bind to specific region(s) of AR to elicit inactivation of AR.
• LNCaP cells were treated with 15 ⁇ of selected active compounds (5, 36, 32, 47 and 48,) for 24 hours and cell viability, AR transcriptional (luciferase) assay and AR western blot analysis were performed.
• active compounds 5, 36, 32, 47 and 48,
• AR transcriptional (luciferase) assay and AR western blot analysis were performed.
• FIG 7 the down-regulation of AR and inhibition of AR mediated transcription occurs before cell growth inhibition, which suggest that compound-induced AR inactivation contributes to their anti-pro liferative activities.
• These compounds also induced significant PARP cleavage in LNCaP and CWR22rvl cells which suggest their abilities to induce apoptosis.
• CYP171dH A truncated version of human CYP17A1 (CYP171dH) was expressed in E. coli and then purified to homogeneity. IC 5 o values of the compounds were determined from dose-response curves and are listed in Table 1.
• IC 50 value is the concentration of inhibitor to inhibit the CYP17 enzyme activity by 50%, each in duplicate. IC 50 values were each determined from dose-response curves.
• IC 50 values of abiraterone alcohol (3b, a CYP17 inhibitor recently approved for prostate cancer therapy), galaterone and 3P-hydroxy-17-(lH-imidazole-l-yl)androsta-5,16-diene (VN/85-1, structure not shown, believed to be the most potent CYP17 inhibitor ) were also determined in the same assay system for comparison (used as positive controls).
• CWR22Rvl cells were used for endogenous levels of splice variant AR- 3. Protein levels were analyzed with respective antibodies; full length AR and ⁇ -actin antibodies were purchased from cell signaling, antibody specific for splice variant AR-3 was obtained from Dr. Yun Qiu, University of Maryland, School of Medicine, Baltimore.
• MTT MTT colorimetric assay
• cells were seeded in 96-well plates (Corning Costar) at a density of 5 x 10 cells per well. The cells were then allowed to adhere to the plate for 24 hours and treated with various concentrations of compounds dissolved in 95% EtOH. The cells were treated for 7 days with renewal of test compound and media on day 4. On the 7th day, medium was renewed and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) (Sigma, St Louis, MO, USA) solution (0.5 mg MTT per ml of media) was added to the medium such that the ratio of MTT: medium was 1 : 10.
• MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
• the cells were incubated with MTT for 2 hours.
• the medium was then aspirated and DMSO was added to solubilize the violet MTT-formazan product.
• the absorbance at 562 nm was measured by spectrophotometry (Biotek Inc.).
• the GI 50 were determined from dose-response curves (by nonlinear regression analysis using GraphPad Prism) compiled from at least three independent experiments, SEM ⁇ 10%, and represents the compound concentration required to inhibit cell growth by 50%.
• C-l 6 modification Tethering aliphatic hydrophobic groups (isopentyl: 25);
• the GI 50 were determined from dose-response curves (by nonlinear regression analysis using GraphPad Prism) compiled from at least three independent experiments using LNCaP cells, SEM ⁇ 10%, and represents the compound concentration required to inhibit cell growth by 50%.
• C-3 modification In an attempt to better understand the role played by OH and O in the ARD/anti-proliferative activities of compounds 5 and 32, and to possibly achieve enhanced interaction with Arg in the AR ligand biding domain, a number of C-3 modified analogs were designed, synthesized and tested. First, oxidation of 5 or reductive alkylation of 32 to give 3- ⁇ - ⁇ 5 compound, 33 and 3 -hydroxy-3 -methyl compound, 40, respectively, lead to significant loss ( ⁇ 5-fold) in anti-proliferative activity (Table 4).
• the GI 50 were determined from dose-response curves (by nonlinear regression analysis using GraphPad Prism) compiled from at least three independent experiments, SEM ⁇ 10%, and represents the compound concentration required to inhibit cell growth by 50%.
• ester based anticancer drugs such as docetaxel, cabazitaxel and esters in clinical development such as bevirimat and related analogs
• three pyridinecarboxylate derivatives of compound 5, including 41-43 were synthesized.
• the biological activities of compounds 41 and 42 were not assessed because of their limited solubilities in ethanol or DMSO.
• the related analogs tethered to lipophilic ester side chain with a carboxylic acid terminus (44-46) exhibited potencies ⁇ 2.5-fold worse than compound 5.
• C-3 carbamates were performed because of: 1) precedence of drugs with carbamate moieties such as the widely use anthielmintics albendazole, fenbendazole and mebendazole; 2) the added feature of lowering the lipohilicity of compound 5, which should also increase solubilities and perhaps physiological relevance.
• carbamate moieties such as the widely use anthielmintics albendazole, fenbendazole and mebendazole
• the imidazoly carbamate 47 with a GI 50 value of 0.87 ⁇ was shown to be the most active, being ⁇ 4-fold superior to compound 5.
• Introduction of 2 ⁇ methyl as in carbamate 48 caused a 6-fold decrease in activity relative to 47, similar to ⁇ 8-fold decrease in activity following replacement of the imidazole moiety with 1,2,4-triazole as exhibited by compound 49.
• the two nitrogen atoms of the Bzlm group of 5 showed no clear interactions with Asn705 and Thr877, unlike the interaction of 9 to Asn705 and Thr877 which occurs through the 17 ⁇ hydro xyl group.
• Silica gel plates (Merck F254) were used for thin-layer chromatography, while flash column chromatography (FCC) was performed on silica gel (230-400 mesh, 60 A). The preparative TLC performed on Silica gel GF (Analtec 500 microns) plates. Pet ether refers to light petroleum, b.p. 40-60 °C.
• Compound 21b prepared by following general method B, refluxing 21a (0.4 g, 0.81 mmol), with 10%) Pd/C (0.4 g, i.e., equal weight of 21a) in dry benzonitrile (7.5 mL) for 4 h. Cooled to room temperature, the catalyst was removed by filtration through a Celite pad. The filtrate was evaporated, and carried to next step without purification.
• 17-(lH-Benzimidazol-l-yl)-androsta-4,16-dien-3-one (32) This compound prepared from 5 as previously described, provided spectral and analytical data as reported.
• 17-(lH-Benzimidazol-l-yl)-androsta-5,16-dien-3-one (33) To a ice cold solution of 5 (0.05 g, 0.13 mmol) in dry DCM (3 mL) was added Dess-Martin periodinane (0.11 g, 0.26 mmol) and the mixture was stirred at ice cold temperature for 5 h. Then it was diluted with ether and was quenched with a mixture of saturated aqueous NaHC0 3 /Na 2 S 2 0 3 (1 :3).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Radiology & Medical Imaging (AREA)
• Pathology (AREA)
• Reproductive Health (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Steroid Compounds (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=51583862

Family Applications (1)

Country Status (13)

Cited By (9)

Families Citing this family (5)

Citations (4)

Family Cites Families (224)

• 2014
  • 2014-03-14 SG SG11201507093WA patent/SG11201507093WA/en unknown
  • 2014-03-14 EP EP22155034.6A patent/EP4066841A1/en active Pending
  • 2014-03-14 AU AU2014236135A patent/AU2014236135A1/en not_active Abandoned
  • 2014-03-14 BR BR112015023098A patent/BR112015023098A2/pt not_active IP Right Cessation
  • 2014-03-14 EP EP14768511.9A patent/EP2968370A4/en not_active Withdrawn
  • 2014-03-14 KR KR1020157029073A patent/KR20150127720A/ko not_active Withdrawn
  • 2014-03-14 RU RU2015137617A patent/RU2015137617A/ru not_active Application Discontinuation
  • 2014-03-14 CA CA2904170A patent/CA2904170A1/en not_active Abandoned
  • 2014-03-14 CN CN201480026739.8A patent/CN105682662A/zh active Pending
  • 2014-03-14 MX MX2015012274A patent/MX2015012274A/es unknown
  • 2014-03-14 WO PCT/US2014/029667 patent/WO2014153215A1/en not_active Ceased
  • 2014-03-14 JP JP2016503188A patent/JP2016514165A/ja active Pending
  • 2014-03-14 US US14/759,555 patent/US9884067B2/en active Active
• 2015
  • 2015-07-08 US US14/794,416 patent/US9439912B2/en active Active
  • 2015-08-25 IL IL240820A patent/IL240820A0/en unknown

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events